The first clinical trial was conducted in 2008 by Kajiyama et al. [39], showing a potential role of HRW in the prevention of T2DM and insulin resistance, as evidenced by normalized glucose tolerance in four of six patients with impaired glucose tolerance (IGT); however, no changes were observed in the levels of FBG and insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.